Association between serum HER2/ErbB2 levels and coronary artery disease: a case-control study

被引:4
作者
Jian, Wen [1 ,2 ,3 ]
Wei, Chun-Mei [1 ,2 ,3 ]
Guan, Jia-Hui [4 ]
Mo, Chang-Hua [1 ]
Xu, Yu-Tao [1 ,2 ,3 ]
Zheng, Wen-Bo [1 ,2 ,3 ]
Li, Lang [1 ,2 ,3 ]
Gui, Chun [1 ,2 ,3 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiol, 06 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China
[2] Guangxi Key Lab Base Precis Med Cardio Cerebrovas, Nanning 530021, Peoples R China
[3] Guangxi Clin Res Ctr Cardiocerebrovasc Dis, Nanning 530021, Guangxi, Peoples R China
[4] Guangxi Med Univ, Affiliated Hosp 1, Dept Resp Med, Nanning 530021, Guangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Coronary artery disease; HER2; ErbB2; Risk factor; GROWTH-FACTOR RECEPTOR; ERBB2; EXPRESSION; TRANSACTIVATION; NEUREGULIN; MECHANISMS; LEPTIN; FAMILY; CELLS; RISK;
D O I
10.1186/s12967-020-02292-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundResearch has associated human epidermal growth factor receptor (HER2) with glucose and lipid metabolism. However, the association between circulating HER2 levels and coronary artery disease (CAD) remains to be elucidated.MethodsWe performed a case-control study with 435 participants (237 CAD patients and 198 controls) who underwent diagnostic coronary angiography from September 2018 to October 2019. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for CAD were calculated with multiple logistic regression models after adjustment for confounders.ResultsOverall, increased serum HER2 levels were independently associated with the presence of CAD (OR per 1-standard deviation (SD) increase: 1.438, 95% CI 1.13-1.83; P=0.003) and the number of stenotic vessels (OR per 1-SD increase: 1.399, 95% CI 1.15-1.71; P=0.001). In the subgroup analysis, a significant interaction of HER2 with body mass index (BMI) on the presence of CAD was observed (adjusted interaction P=0.046). Increased serum HER2 levels were strongly associated with the presence of CAD in participants with BMI >= 25 kg/m(2) (OR per 1-SD increase: 2.143, 95% CI 1.37-3.35; P=0.001), whereas no significant association was found in participants with BMI<25 kg/m(2) (OR per 1-SD increase: 1.225, 95% CI 0.90-1.67; P=0.201).ConclusionElevated HER2 level is associated with an increased risk of CAD, particularly in people with obesity. This finding yields new insight into the pathological mechanisms underlying CAD, and warrants further research regarding HER2 as a preventive and therapeutic target of CAD.
引用
收藏
页数:10
相关论文
共 43 条
[2]   HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion [J].
Bao, Wei ;
Fu, Hai-Jing ;
Jia, Lin-Tao ;
Zhang, Yong ;
Li, Wei ;
Jin, Bo-Quan ;
Yao, Li-Bo ;
Chen, Si-Yi ;
Yang, An-Gang .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2010, 499 (1-2) :49-55
[3]   Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy [J].
Beltowski, Jerzy ;
Jazmroz-Wisniewska, Anna .
CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (04) :616-624
[4]   HER2 induces expression of leptin in human breast epithelial cells [J].
Cha, Yujin ;
Kang, Youjin ;
Moon, Aree .
BMB REPORTS, 2012, 45 (12) :719-723
[5]   The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis [J].
Dreux, AC ;
Lamb, DJ ;
Modjtahedi, H ;
Ferns, GAA .
ATHEROSCLEROSIS, 2006, 186 (01) :38-53
[6]   Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer [J].
Duchnowska, Renata ;
Loibl, Sibylle ;
Jassem, Jacek .
CANCER TREATMENT REVIEWS, 2018, 67 :71-77
[7]   Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System [J].
Forrester, Steven J. ;
Kawai, Tatsuo ;
O'Brien, Shannon ;
Thomas, Walter ;
Harris, Raymond C. ;
Eguchi, Satoru .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56, 2016, 56 :627-653
[8]   Characteristics of coronary artery disease in chronic kidney disease [J].
Fujii, Hideki ;
Kono, Keiji ;
Nishi, Shinichi .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (06) :725-732
[9]  
Hedhli N, 2014, CURR PHARM DESIGN, V20, P4899
[10]   HER2+breast cancer treatment and cardiotoxicity: monitoring and management [J].
Jerusalem, Guy ;
Lancellotti, Patrizio ;
Kim, Sung-Bae .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (02) :237-250